SCHEMBL2493840

SCHEMBL2493840

O=C(Nc1ccc(Cl)c(C(=O)Nc2cnc(Nc3ccc(O)cc3)nc2)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 12/20 0.79
LCK P06239 7/20 0.69
CSF1R P07333 5/20 0.69
JAK2 O60674 1/20 0.69
PDGFRB P09619 1/20 0.69
FGFR1 P11362 1/20 0.69
CYP2C9 P11712 1/20 0.69
BRAF P15056 1/20 0.69
EPHB4 P54760 1/20 0.69
PTK2 Q05397 1/20 0.69
MAPK14 Q16539 1/20 0.69
BLK P51451 4/20 0.63
KCNQ3 O43525 1/20 0.61
KCNQ2 O43526 1/20 0.61
KCNE1 P15382 1/20 0.61
KCNQ1 P51787 1/20 0.61
KCNQ5 Q9NR82 1/20 0.61
EGFR P00533 1/20 0.60
ERBB2 P04626 1/20 0.60
TEC P42680 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2497726 0.93 BTK (0.83) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL2500744 0.89 BTK (0.74) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL2491995 0.89 CSF1R (0.84) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL12212487 0.89 BTK (0.88) BTKLCKCSF1RMAPK14BLK
SCHEMBL15998211 0.88 BTK (1.00) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL2495621 0.88 BTK (0.75) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL12190189 0.87 BTK (0.71) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL15998163 0.86 BTK (0.81) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL2494570 0.85 CSF1R (0.81) BTKLCKCSF1RJAK2PDGFRB
SCHEMBL14286496 0.85 CSF1R (0.75) BTKLCKCSF1RJAK2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 BTK 44/4885LCK 9/4885CSF1R 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.